This could be material info and you should be careful in your communications, and more importantly describing those inside communications with a posting board.

Before y’all jump down my throat, yes, this is material if it affects a clinical trial that there is a known issue that the public doesn’t know about.

And always, CEO gets credit and blame. This is on him.